The ISPOR mission is to translate pharmacoeconomics and outcomes research into practice. We encourage health care practitioners, health care purchasers, and health care decision-makers, as well as pharmacoeconomic and outcomes researchers to attend this meeting.	In this program, SPECIAL TRACKS are identified for the following:
		Health care practitioner (physician, pharmacist, nurse, other health care professionals)
		Health care decision-maker & purchaser (health plans, insurance companies, government)
		Outcomes (quality-of-life) researchers
		Pharmacoeconomic (health economic) researchers
	Choose your TRACK and follow the symbol in the program to help you select presentations that match your interest.

Monday, May 24, 1999
7:00AM - 8:00AM	CONTINENTAL BREAKFAST IN FOYER
7:00AM - 8:00AM	CONTRIBUTED WORKSHOP SESSION 1 PRESENTER MEETING
7:00AM - 8:00AM	ISPOR QUALITY OF LIFE DISCUSSION GROUP MEETING (open invitation)
8:00AM - 10:30AM	FIRST GENERAL SESSION
8:00AM - 8:10AM	OPENING REMARKS Jon Clouse MS, Executive Vice President, Ingenix Pharmaceutical Services, Eden Prairie, MN, USA, Fourth Annual International Meeting Chair and First General Session Discussion Leader
8:10AM - 8:30AM	ISPOR PRESIDENTIAL ADDRESS Robert Epstein MD, MS, Senior Vice President, Merck-Medco Managed Care, Montvale, NJ, USA and 1998-99 ISPOR President
8:10AM - 8:30AM	"WHAT NEEDS TO CHANGE TO ASSURE VALUE FOR YOUR HEALTH CARE DOLLAR" Keynote Speaker: David Kindig MD, PhD, Professor of Preventive Medicine and Vice Chancellor of Health Science, University of Wisconsin, Madison, WI, USA and author of "Purchasing Population Health: Paying for Results" Dr. Kindig will address whether cost-effectiveness and other economic analyses can be effectively incorporated into health policy decision making to assure value for the health care dollar. Responders: • Lee Newcomer MD, Senior Vice President Health Policy and Strategy, United Health Group, Minnetonka, MN, USA • Peter Penna PharmD, Vice President, Manage Pharmacy, Cigna HealthCare, Hartford, CT, USA Dr. Newcomer and Dr. Penna will respond to Dr. Kindig's approach to establish value and make payment to health care providers on the basis of outcomes achieved as well as respond to how Dr. Kindig's plan could be implemented within and across managed health care systems. Dr. Kindig's approach will be contrasted with the evaluation of the health care system as it currently exists through HEDIS and NCQA.
10:30AM - 11:00AM	POSTER PRESENTATIONS, EXHIBITS, AND REFRESHMENTS IN EXHIBIT HALL Click here for Poster Presentation Titles
11:00AM - 12:30PM	PODIUM PRESENTATIONS - CONTRIBUTED PAPERS
	ECONOMIC & OUTCOMES ISSUES IN CARDIOVASCULAR DISEASE Moderator: Diana I. Brixner RPh, PhD, Vice President Health Care Management, Novartis Pharmaceuticals, East Hanover, NJ, USA, and Director, ISPOR Executive Board
11:00 - 11:20	CD1	HOSPITAL UTILIZATION AND COST AMONG PATIENTS WITH NONISCHEMIC HEART FAILURE IN THE FIRST PROSPECTIVE RANDOMIZED AMLODIPINE SURVIVAL EVALUATION STUDY (PRAISE) Radensky PW2, O'Connor CM1, Unger AN3, Martin BC4, 1Duke University Medical Center, Durham NC, USA; 2Hurley Consulting Associates, Ltd., Boca Raton, FL, USA; 3SAIC, Reston, VA, USA; 4College of Pharmacy, University of Georgia, Athens, GA, USA
11:20 - 11:40	CD2	ABCIXIMAB IN PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY: A MULTICENTER OBSERVATIONAL STUDY Cheu C, Krumholz H, Cocks D, McGee D, Morton D, Vlasses PH, University HealthSystem Consortium, Oak Brook, IL, USA
11:40 - 12:00	CD3	EXCESS STROKE AMONG HYPERTENSIVE MEN AND WOMEN ATTRIBUTABLE TO UNDERTREATMENT OF HYPERTENSION Klungel OH1,2,3, Stricker BHCh2, Paes AHP1, Seidell JC3, Bakker A1, Zoltán V2, Breteler MMB2, de Boer A1, 1Department of Pharmacoepidemiology & Pharmacotherapy, Utrecht University, Utrecht, The Netherlands; 2Department of Epidemiology & Biostatistics, Erasmus University Medical School, Rotterdam, The Netherlands; 3Department of Chronic Diseases and Environmental Epidemiology, National Institute of Public Health and the Environment, Bilthoven, The Netherlands
12:00 - 12:20	CD4	LEFT VENTRCULAR SYSTOLIC FUNCTION AND 90-DAY HOSPITAL READMISSION IN CONGESTIVE HEART FAILURE PATIENTS - IMPLICATIONS AND DISEASE MANAGEMENT Wang AY1, Thomas J1, Schiff GD2, Stamos TD3, Weiss KB3, 1Pharmacy School, Purdue University, IN, USA; 2The Cook County Hospital, IL, USA; 3Rush-Presbyterian-St.Luke's Medical Center, IL, USA
12:20	QUESTIONS AND DISCUSSION
	ECONOMIC & OUTCOMES ISSUES IN MENTAL HEALTH Moderator: Thomas Einarson PhD, Associate Professor, University of Toronto, Toronto, Ontario, Canada, and Director, ISPOR Executive Board
11:00 - 11:20	ND1	INPATIENT COST AND RESOURCE UTILIZATION FOR PARKINSON'S DISEASE Doshi DP, Chatterton ML, Thomas Jefferson University, Philadelphia, PA, USA
11:20 - 11:40	ND2	POTENTIAL SAVINGS IN THE COST OF TREATING ALZHEIMER'S DISEASE: INPATIENT TREATMENT WITH RIVASTIGMINE Hauber AB1, Gnanasakthy A2, Snyder EH3, Richter A1, Mauskopf JA1, 1Research Triangle Institute, Research Triangle Park, NC, USA; 2Novartis Pharma AG, Basel, Switzerland; 3Novartis Pharmaceuticals, East Hanover, NJ, USA
11:40 - 12:00	ND3	AN OUTCOMES MEASURE FOR NONINSTITUTIONALIZED SCHIZOPHRENIC CONSUMERS Barr JT, Schumacher GE, Mason EJ, Ohman SM, Hanson A, Northeastern University, Boston, MA, USA, and Massachusetts Division of Medical Assistance, Boston, MA, USA
12:00 - 12:20	ND4	ASSESSING UTILITIES FOR DEPRESSION OUTCOMES: PREFERENCES OF DEPRESSED PATIENTS AND THE GENERAL PUBLIC Gonzales J, Bowers B, Weinfurt K, Bajwa K, Harvey J, Schulman K, Clinical Economics Research Unit, Depts of Psychiatry and Medicine, Georgetown University Medical Center, Washington DC, USA
12:20	QUESTIONS AND DISCUSSION
	ECONOMIC & OUTCOMES ISSUES OF RESPIRATORY DISEASE Moderator: Bryan Luce PhD, MBA, President, MEDTAP International, Bethesda, MD, USA, and ISPOR President-elect
11:00 - 11:20	RD1	TREATING ALLERGIC RHINITIS IN PATIENTS WITH COMORBID ASTHMA: THE RISK OF ASTHMA RELATED HOSPITALIZATIONS AND EMERGENCY ROOM VISITS Crystal-Peters J1, Neslusan C1, Crown B1, Torres A1, Creticos P2, 1The Medstat Group Inc., Washington, DC, USA; 2Johns Hopkins Asthma and Allergy Clinic, Baltimore, MD, USA
11:20 - 11:40	RD2	COST-EFFICACY ANALYSIS OF AN INHALED CORTICOSTEROID VERSUS A LEUKOTRIENE RECEPTOR ANTAGONIST Carranza-Rosenzweig JR1, Bowers BW1, Stanford RH1 and Edwards LD1, 1Glaxo-Wellcome Inc., Research Triangle Park, NC, USA
11:40 - 12:00	RD3	CYSTIC FIBROSIS; AGGRESSIVE INTERVENTION IS ASSOCIATED WITH IMPROVED OUTCOME Johnson C1, Wohl ME2, Butler SM1, 1Medical Affairs, Genentech Inc., South San Francisco, CA, USA; 2CF Center, Children's Hospital Medical Center, Boston, MA, USA
12:00 - 12:20	RD4	RELATIONSHIP AMONG DISEASE-SPECIFIC QUALITY OF LIFE AND CLINICAL CONSEQUENCES OF ASTHMA Kozma, CM1, Slaton, TL1, Watrous, ML2; 1University of South Carolina, Columbia, SC; 2Genentech, Inc., South San Francisco, CA, USA
12:20	QUESTIONS AND DISCUSSION
	ECONOMIC & OUTCOMES ISSUES OF INFECTIOUS DISEASE Moderator: Peter Davey MD, FRCP, Head of Pharmacoeconomics, University of Dundee, Dundee, Scotland, and Director, ISPOR Executive Board
11:00 - 11:20	ID1	ESTIMATING THE COST-EFFECTIVENESS OF ANTIBIOTIC TREATMENT FOR ACUTE OTITIS MEDIA USING VARIABLE SETIMATION TECHNIQUES Brooks JM1, Park TR1, Klepser K2, 1Program in Pharmaceutical Socioeconomics, University of Iowa, College of Pharmacy, Iowa City, IA, USA; 2Division of Clinical and Administrative Pharmacy University of Iowa, College of Pharmacy, Iowa City, IA, USA
11:20 - 11:40	ID2	CHRONIC HEPATITIS C: COST-EFFECTIVENESS OF INTERFERON AND RIBAVIRIN Singer ME1, Shermock K2, Younossi ZM2, 1Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, USA; 2Cleveland Clinic Foundation, Cleveland, OH, USA
11:40 - 12:00	ID3	ADDITIONAL ANTIBIOTIC UTILKIZATION IN A RANDOMIZED TRIAL OF CLARITHROMYON (CLARI) COMPARED WITH AZITHROMYCIN (AZI) FOR THE TREATMENT OF S. PYOGENES PHARYNGITIS/TONSILLITIS Chang RJ, Busman T, Ryan J, Zhang J, Devcich K, Conway PD, Abbott Laboratories, Abbott Park, IL, USA
12:00 - 12:20	ID4	A COST ANALYSIS OF LEVOFLOXACIN VERSUS CEFTRIAXONE IN ADULT INPATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA Rittenhouse BE1,2, Stinnett AA1,3, Dulisse B1, Henke CJ4,5, Potter L4, Parasuraman B1, Martens LL1, Williams RR6, Kojak C6, 1ICOM Health Economics, Johnson & Johnson, Raritan, NJ, USA; 2Robert Wood Johnson Hospital, New Brunswick, NJ, USA; 3University of Alabama, Birmingham, AL, USA; 4TAG-Lewin, San Francisco, CA, USA; 5University of California at San Francisco, San Francisco, CA, USA; 6Robert Wood Johnson Pharmaceutical Research Institute, Raritan, NJ, USA
12:20	QUESTIONS AND DISCUSSION
12:30 - 1:30PM	LUNCH IN EXHIBIT HALL
1:30 - 3:30PM	PODIUM PRESENTATIONS - CONTRIBUTED PAPERS
	DISEASE (HEALTH) MANAGEMENT RESEARCH Moderator: Robert Epstein MD, MS, Executive Vice President, Merck Medco Managed Care, Montvale, NJ, USA and 1998-99 ISPOR President
1:30 - 1:50	DM1	RANDOMIZED EVALUATION OF A DISEASE MANAGEMENT PROGRAM FOR DYSPEPSIA IN A MANAGED CARE SETTING Segal R1, Ofman J2, Weingarten S2, Russell W1, Lowenstein E, Zinkovich L, Meuser D, Pourfarzib R, Blanchette E, Mazanec W, Kernodle S, 1University of Florida, Gainesville, FL, USA; 2Zynx Health Inc., Los Angeles, CA, USA
1:50 - 2:10	DM2	MEASURING THE EFFECTIVENESS OF A DIABETES DISEASE MANAGEMENT PROGRAM Jackson A, Borenstein J, Deutsch S, Relan A, Harris M, Arce K, Weingarten S Cedars-Sinai Health System, Los Angeles, California USA
2:10 - 2:30	DM3	IMPLEMENTATION OF NATIONAL CHOLESTEROL GUIDELINES: A MULTIDISCIPLINARY APPROACH TO HYPERLIPIDEMIA DISEASE MANAGEMENT Borenstein J1, Saltiel M1, Kaye S1, Wright N1, Graber G1, Deutsch S1, Weingarten S1, 1Cedars-Sinai Health System, Los Angeles, CA, USA
2:30 - 2:50	DM4	COST-EFFECTIVENESS OF OCCUPATIONAL THERAPY ON HEALTHY ELDERLY PEOPLE Luo R, Hay J, Clark F, Azen S, University of Southern California, Los Angeles, CA, USA
2:50	QUESTIONS AND DISCUSSION
	OUTCOMES RESEARCH METHODS Moderator: James Smeeding RPh, MBA, Associate Director, Center for Pharmacoeconomic Studies, University of Texas, Austin, TX, USA, and ISPOR Past President
1:30 - 1:50	RM1	CONTROLLING FOR SIMULTANEITY BIAS IN OUTCOME STUDIES USING PANEL DATA Luo R, Hay J, Hsiao C, The University of Southern California, Los Angeles, CA, USA
1:50 - 2:10	RM2	COSTS OF HEALTH CARE FOR EIGHT YEARS PRIOR TO RECOGNITION OF TYPE 2 DIABETES (DM2) Nichols GA, Brown JB, Center for Health Research, Portland, OR, USA
2:10 - 2:30	RM3	THE USE OF ABCIXIMAB FOR PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY PATIENTS ENROLLED IN MANAGED CARE ORGANIZATIONS Lage M1, Barber B2, Bowman L2, Ball D2, Bala M3, 1Miami University, Oxford, OH, USA; 2Eli Lilly and Company, Indianapolis, IN, USA; 3Centocor Inc, Malvern PA, USA
2:30 - 2:50	RM4	OUTCOME ASSESSMENT OF A FALL RISK-REDUCTION PROGRAM: METHODOLOGICAL ISSUES Maynard PW1, Slattum PW1,2, 1Heritage Information Systems, Inc., Richmond, VA, USA; 2School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA
2:50	QUESTIONS AND DISCUSSION
	NEW ECONOMIC RESEARCH METHODS Moderator: J. Lyle Bootman MS, PhD, Dean & Professor, College of Pharmacy, University of Arizona, Tucson, AZ, USA, and Director, ISPOR Executive Board
1:30 - 1:50	ER1	THE APPLICATION OF MULTI-LEVEL MODELLING AND CLUSTER ANALYSIS TO MULTINATIONAL EVALUATION DATA Pang F, Centre for Health Economics, University of York, York, UK
1:50 - 2:10	ER2	PRICE ELASTICITY OF PEOPLE'S WILLINGNESS TO PAY IN PATIENTS WITH URINARY INCONTINENCE Budhiarso I, Bushnell DM, Health Research Associates, Inc, Seattle, WA, USA
2:10 - 2:30	ER3	OSTEOPOROSIS MARKOV MODEL: EVALUATING THE IMPACT OF DISCOUNTING AND AGE ADJUSTED FRACTURE RATES ON COST EFFECTIVENESS RATIOS AND MARKOV ANALYSIS Keys P, Wayne State University College of Pharmacy and AHP, Detroit, MI, USA
2:30 - 2:50	ER4	MODELING PHARMACOECONOMIC ANALYSES WITH DISTRIBUTIONS OF RESULTS FROM TRIALS Smith D, University of Michigan, Ann Arbor, MI, USA
2:50	QUESTIONS AND DISCUSSION
	DRUG POLICY RESEARCH Moderator: Gordon J. Vanscoy PharmD, MBA, Vice President, Managed Health Care Division, Stadtlanders Drug, Pittsburgh, PA, USA, and Director, ISPOR Executive Board
1:30 - 1:50	DP1	EFFECT OF DEMOGRAPHICS ON THE COST OF PHARMACEUTICALS IN A PRIVATE THIRD-PARTY PRESCRIPTION PROGRAM Momin SR , Larrat EP, Harlow LL, University of Rhode Island, Kingston, RI, USA
1:50 - 2:10	DP2	THE RELATIONSHIP BETWEEN PAYER TYPE AND HOSPITALIZATION RATES FOR ASTHMATICS SUBSEQUENT TO AN EMERGENCY ROOM VISIT Stanford RH1, Okamoto LJ2, McLaughlin TP2, 1Glaxo Wellcome Inc, Research Triangle Park, NC, USA; 2NDC Health Information Services, Phoenix, AZ, USA
2:10 - 2:30	DP3	USING SIMULATION MODELLING TECHNIQUES TO FACILITATE THE MANAGEMENT OF THE WAITING LIST FOR LIVER TRANSPLANTATION Ratcliffe J1,Young1, Eldabi T2, 1Health Economics Research Group, Brunel University; 2Centre for Applied Simulation Modelling, Dept of Computer Sciences, Brunel University, Uxbridge, UK
2:30 - 2:50	DP4	USING COST OF ILLNESS STUDIES IN HEALTH CARE POLICY MAKING Bloom BS, Bruno D, Kahn A, Maman DY, University of Pennsylvania, Philadelphia, PA, USA
2:50	QUESTIONS AND DISCUSSION
3:00PM	BEVERAGES IN FOYER
CONTRIBUTED WORKSHOPS ARE HELD ON: Session 1: Monday 3:00 - 3:50pm and repeated at 4:00 - 4:50pm   Session 2: Tuesday 3:00 - 3:50pm and repeated at 4:00 - 4:50pm   Session 3: Wednesday 8:00 - 8:50am and repeated at 9:00 - 9:50am   CONTRIBUTED WORKSHOP TOPICS ARE: SERIES CODE Series 1: Designing and Conducting Pharmacoeconomic Studies That Get Used WPE Series 2: Issues in the Development of Treatment Guidelines WTG Series 3: Practical Issues in the Use of Pharmacoeconomic in Decision-Making WDM Series 4: Methodology Issues     Methodology Issues - Modeling WMM   Methodology Issues - Statistical Issues WMS   Methodology Issues - Data Collection WMD   Methodology Issues - Quality of Life Instruments WMQ
3:00 - 3:50PM	CONTRIBUTED WORKSHOPS - SESSION 1
	WPE1	MODELING FOR POLICY MAKERS THE EXPECTED BENEFITS OF PREVENTION Leader S, Muhuri P, Pracon, Reston, VA, USA
	WPE2	THE NUTS AND BOLTS OF CONDUCTING RANDOMIZED OUTCOMES TRIALS Menzin J, Friedman M, Boston Health Economics, Inc., Billerica, MA, USA
	WPE3	HEALTH ECONOMISTS AND MANAGED CARE DECISION MAKERS: BRIDGING THE GAP Bala MV1, Westrick E2, Mauskopf JA3, 1Centocor, Inc., Malvern, PA, USA; 2MIM Health Plans, Providence, RI, USA; 3Research Triangle Institute, Research Triangle Park, NC, USA
	WPE9	BEGIN WITH THE END IN MIND: ISSUES IN PLANNING PHARMACOECONOMIC RESEARCH FOR MORE EFFECTIVE COMMUNICATION Rindress D, Goetghebeur M, Welner S, McTavish A, BioMedCom Consultants Inc, Montreal, Québec, Canada
	WTG1	APPLES AND APPLES, APPLES AND ORANGES: THE USE AND ABUSE OF AVERAGE DAILY DOSE IN PHARMACOECONOMIC RESEARCH Loosbrock D1, Gibson J1, Dulisse B1,2, Edgell E3, Kody M3, 1Health Outcomes Evaluation Group, Eli Lilly and Company, Indianapolis, IN, USA; 2Statistical and Mathematical Sciences, Eli Lilly and Company, Indianapolis, IN, USA; 3Global Health Outcomes Research, Eli Lilly and Company, Indianapolis, IN, USA
	WTG6	MAKING DECISIONS ABOUT ANTIBIOTIC RESISTANCE Davey PG, University of Dundee, MEMO, Dundee, Scotland
	WDM1	CURRENT COMPUTER SOFTWARE AND HARDWARE OPTIONS IN PHARMACO-ECONOMICS: SPREADSHEETS, DECISION ANALYSIS, INTERNET, AND EDUCATIONAL TOOLS McGhan WF, University of the Sciences in Philadelphia, Philadelphia, PA, USA
	WMM1	IS THE CURRENT RELIANCE ON THE MARKOV ASSUMPTION IN ECONOMIC MODELS JUSTIFIED? Caro JJ, Huybrechts KF, Caro Research, Boston, MA, USA
	WMM2	ECONOMIC EVALUATION OF PROSPECTIVE MULTINATIONAL CLINICAL TRIALS: A MODELING APPROACH Hux M 1, Weinstein M1,2, Torrance G1,3, 1 Innovus Research Inc., Burlington, ON, Canada; 2Harvard School of Public Health, Boston MA, USA; 3McMaster University, Hamilton, ON, Canada
	WMS1	ESTIMATING MEDICAL COSTS FROM INCOMPLETE FOLLOWUP DATA Polsky D, Glick H, University of Pennsylvania, Philadelphia, PA, USA
	WMD1	DATA COLLECTION METHODS FOR RESOURCE UTILIZATION: CHOOSING THE RIGHT APPROACH Crawford B, Evans C, MAPI Values, Boston, MA, USA
	WMQ1	THE SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM HEALTH QUESTIONNAIRE (SCAP_HQ): A BRIEF INSTRUMENT TO ASSESS OUTCOMES OF CARE IN SCHIZOPHRENIA Johnstone BM1, Loosbrock DL1, Lehman AF2, Fischer EP3, Postrado L2, Delahanty J2, Russo PA4, 1Health Outcomes Evaluation Group, United States Medical Division, Eli Lilly and Company, Indianapolis, IN, USA; 2Center for Mental Health Services Research, University of Maryland, Baltimore, MD, USA; 3Center for Mental Healthcare Research, University of Arkansas for Medical Sciences, Little Rock, AR, USA; 4The Medstat Group, Washington, D.C., USA
4:00 - 4:50PM	CONTRIBUTED WORKSHOPS - SESSION 1R (A repeat of SESSION 1 workshops)
5:00PM - 6:00PM	ISPOR BUSINESS MEETING
6:00PM - 7:00PM	EXHIBITORS WELCOME RECEPTION IN EXHIBIT HALL Chamber music provided by the FDA Trio (Mary Andrich, Laurie Beth Burke and Lisa Kammerman)
7:00PM - 8:00PM	VALUE IN HEALTH EDITORIAL ADVISORY BOARD RECEPTION (by invitation only)

Annual International Meeting Main Page